Cargando…

HDAC Inhibition by LBH589 Affects Phenotype and Function of Human Myeloid Dendritic Cells

LBH589 is a novel pan-HDAC inhibitor which has potent antitumor activity in multiple myeloma and other hematologic malignancies. However, its impact on immune system has not been defined. We here evaluated the effects of LBH589 on human myeloid dendritic cells (DCs) at clinically relevant concentrat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, W, Tai, Y-T, Tian, Z, Hideshima, T, Chauhan, D, Nanjappa, P, Exley, M A, Anderson, K C, Munshi, N C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2010
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3839585/ https://www.ncbi.nlm.nih.gov/pubmed/21102427 http://dx.doi.org/10.1038/leu.2010.244

Ejemplares similares

HDAC Inhibitor LBH589 Suppresses the Proliferation but Enhances the Antileukemic Effect of Human γδT Cells
por: He, Ying, et al.
Publicado: (2020)

LBH589, A Hydroxamic Acid-Derived HDAC Inhibitor, is Neuroprotective in Mouse Models of Huntington’s Disease
por: Chopra, Vanita, et al.
Publicado: (2016)

The HDAC Inhibitor LBH589 Induces ERK-Dependent Prometaphase Arrest in Prostate Cancer via HDAC6 Inactivation and Down-Regulation
por: Chuang, Mei-Jen, et al.
Publicado: (2013)

A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma
por: Ibrahim, Nageatte, et al.
Publicado: (2016)

Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer
por: Garrett, Leslie A., et al.
Publicado: (2016)

Knockdown of MTDH Sensitizes Endometrial Cancer Cells to Cell Death Induction by Death Receptor Ligand TRAIL and HDAC Inhibitor LBH589 Co-Treatment
por: Meng, Xiangbing, et al.
Publicado: (2011)

LBH589 Inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/stat3/akt pathway
por: Song, Xuan, et al.
Publicado: (2013)

The HDAC Inhibitors Scriptaid and LBH589 Combined with the Oncolytic Virus Delta24-RGD Exert Enhanced Anti-Tumor Efficacy in Patient-Derived Glioblastoma Cells
por: Berghauser Pont, Lotte M.E., et al.
Publicado: (2015)

Combination Therapy with the Histone Deacetylase Inhibitor LBH589 and Radiation Is an Effective Regimen for Prostate Cancer Cells
por: Xiao, Weiwei, et al.
Publicado: (2013)

The Histone Deacetylase Inhibitor LBH589 (Panobinostat) Modulates the Crosstalk of Lymphocytes with Hodgkin Lymphoma Cell Lines
por: Klein, Jan M., et al.
Publicado: (2013)

Sustained Low-Dose Treatment with the Histone Deacetylase Inhibitor LBH589 Induces Terminal Differentiation of Osteosarcoma Cells
por: Cain, Jason E., et al.
Publicado: (2013)

Panobinostat (LBH589) combined with AM1241 induces cervical cancer cell apoptosis through autophagy pathway
por: Sheng, Bo, et al.
Publicado: (2023)

The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of adoptively transferred CD8+ T cells
por: Lisiero, Dominique N, et al.
Publicado: (2014)

Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells
por: Yan-Fang, Tao, et al.
Publicado: (2015)

Mevastatin blockade of autolysosome maturation stimulates LBH589-induced cell death in triple-negative breast cancer cells
por: Lin, Zhaohu, et al.
Publicado: (2017)

c-FLIP Degradation Mediates Sensitization of Pancreatic Cancer Cells to TRAIL-Induced Apoptosis by the Histone Deacetylase Inhibitor LBH589
por: Kauh, John, et al.
Publicado: (2010)

DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines
por: LaBonte, Melissa J, et al.
Publicado: (2009)

Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor
por: Hamberg, Paul, et al.
Publicado: (2011)

Convection enhanced delivery of panobinostat (LBH589)-loaded pluronic nano-micelles prolongs survival in the F98 rat glioma model
por: Singleton, WG, et al.
Publicado: (2017)

Effects of Histone Deacetylase Inhibitor Panobinostat (LBH589) on Bone Marrow Mononuclear Cells of Relapsed or Refractory Multiple Myeloma Patients and Its Mechanisms
por: Ma, Yanping, et al.
Publicado: (2017)

LBH589, a deacetylase inhibitor, induces apoptosis in adult T-cell leukemia/lymphoma cells via activation of a novel RAIDD-caspase-2 pathway
por: Hasegawa, H, et al.
Publicado: (2011)

The Bcl-2 inhibitor Obatoclax overcomes resistance to histone deacetylase inhibitors SAHA and LBH589 as radiosensitizers in patient-derived glioblastoma stem-like cells
por: Berghauser Pont, Lotte M.E., et al.
Publicado: (2014)

Combination of Histone Deacetylase Inhibitor Panobinostat (LBH589) with β-Catenin Inhibitor Tegavivint (BC2059) Exerts Significant Anti-Myeloma Activity Both In Vitro and In Vivo
por: Savvidou, Ioanna, et al.
Publicado: (2022)

Overexpression of LBH is associated with poor prognosis in human hepatocellular carcinoma
por: Chen, Jiewei, et al.
Publicado: (2018)

Hypoxia induced LBH overexpression accelerates malignant progression in glioma
por: Zhang, Ke-Nan, et al.
Publicado: (2019)

HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications
por: Harada, Takeshi, et al.
Publicado: (2017)

589 Urticaria Pigmentosa. Case Report
por: González-Díaz, Sandra, et al.
Publicado: (2012)

Zebrafish Lbh-like Is Required for Otx2-mediated Photoreceptor Differentiation
por: Li, Wen-Hua, et al.
Publicado: (2015)

Limb‐bud and heart development (LBH) contributes to glioma progression in vitro and in vivo
por: Liu, Luotong, et al.
Publicado: (2021)

Exosomal LBH inhibits epithelial-mesenchymal transition and angiogenesis in nasopharyngeal carcinoma via downregulating VEGFA signaling
por: Wu, Anbiao, et al.
Publicado: (2022)

P589: IMPLICATIONS OF REGISTRY DATA FOR ACUTE MYELOID LEUKEMIA (AML) TREATMENT AND CARE DURING THE COVID-19 PANDEMIC
por: Scott, Bart, et al.
Publicado: (2023)

HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer
por: Hideshima, Teru, et al.
Publicado: (2017)

HDAC Inhibitors in Acute Myeloid Leukemia
por: San José-Enériz, Edurne, et al.
Publicado: (2019)

589. Impact of Parents and the Environment on MRSA Transmission in the Neonatal ICU
por: Reich, Patrick J, et al.
Publicado: (2019)

MON-589 Studying Mechanisms of Satiety in the Human Ileum and Colon
por: Ramgulam, Anya, et al.
Publicado: (2020)

ODP589 Acute Hypercalcemic Crisis in an Elderly with Granulomatous Disease
por: Capellan, Maria Leonora, et al.
Publicado: (2022)

A novel proteasome inhibitor NPI-0052 as an anticancer therapy
por: Chauhan, D, et al.
Publicado: (2006)

Correction: HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer
por: Hideshima, Teru, et al.
Publicado: (2021)

SAT-589 Thyrotoxic Periodic Paralysis: A Rare Presentation of Thyrotoxicosis
por: Fatima, Nishat, et al.
Publicado: (2019)

Bioinformatic analysis of the expression and prognosis of ZNF589 in human breast cancer
por: Fan, Jun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r2q2nvsljvs3gjv3b7bd6v99v4